New Zealand markets closed

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.90-0.74 (-6.95%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5532.36M
Enterprise value 3519.66M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-8.20%
S&P500 52-week change 333.64%
52-week high 376.99
52-week low 36.43
50-day moving average 310.20
200-day moving average 317.94

Share statistics

Avg vol (3-month) 33.71M
Avg vol (10-day) 32.22M
Shares outstanding 553.77M
Implied shares outstanding 6N/A
Float 818.03M
% held by insiders 164.98%
% held by institutions 14.00%
Shares short (29 Sep 2021) 41.7M
Short ratio (29 Sep 2021) 41.11
Short % of float (29 Sep 2021) 4N/A
Short % of shares outstanding (29 Sep 2021) 43.16%
Shares short (prior month 30 Aug 2021) 42.26M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -28.79M
Net income avi to common (ttm)-347.61M
Diluted EPS (ttm)-26.14
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.39M
Total cash per share (mrq)0.28
Total debt (mrq)686.17k
Total debt/equity (mrq)N/A
Current ratio (mrq)0.52
Book value per share (mrq)-0.36

Cash flow statement

Operating cash flow (ttm)-15.95M
Levered free cash flow (ttm)N/A